BCLM patients with HR+/HER2+ subtype displayed the longest median survival than HR+/HER2- and triple-negative patients due to the introduction of HER2-targeted therapy and therefore it should be recommended for HER2+ BCLM patients.īreast cancer HER2-targeted therapy Liver metastasis Prognostic factors Risk factors. For those who underwent HER2-targeted therapy, however, HR+/HER2+ subtype reduced death risk compared with HR+/HER2- subtype (HR = 0.74 95% CI = 0.58-0.95 P < 0.001).īreast cancer patients at a high risk for developing liver metastasis deserve more attention during the follow-up. Breast cancer is one of the most common malignancies among women, with an estimated 2.3 million new cases each year worldwide. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR) = 2.62 95% confidence interval (CI) = 1.88-3.66 P < 0.001) and HR-/HER2+ (HR = 3.43 95% CI = 2.28-5.15 P < 0.001) were associated with a significantly increased death risk in comparison with HR+/HER2- patients if these patients did not receive HER2-targeted therapy. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. Although such difference was statistically significant only in the axillary lymph node status. In our study, the mean value of ADC was lower in the positive axillary lymph node, HER2-positive, ER-negative, and PR-negative groups. Molecular subtypes also played a critical role in the survival of BCLM patients. However, few studies have reported the relationship between ADC value and the prognostic factors of breast cancer. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Patients with MBC represent a heterogeneous group whose prognosis and outcome may be dependent on host factors. Young age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and human epidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. Background: Treatment of metastatic breast cancer (MBC) remains palliative. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients. Logistic regression was used to identify risk factors for liver metastasis. ![]() The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM).ĭata on 311,573 breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. ![]() Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |